Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA)
· seekingalpha.com
Cabaletta Bio (CABA) CAR-T for autoimmune disease: EULAR 2026 data, $2.90 entry, $150M raise, 2H27 BLA path, and upside potential—read now.
It has been a bit, but I am back with the 5 th piece in my CAR-T coverage arc. For those of you who are new to my writing, my flagship thesis revolves around CA...